| Literature DB >> 17287850 |
V H J van der Velden1, G Cazzaniga, A Schrauder, J Hancock, P Bader, E R Panzer-Grumayer, T Flohr, R Sutton, H Cave, H O Madsen, J M Cayuela, J Trka, C Eckert, L Foroni, U Zur Stadt, K Beldjord, T Raff, C E van der Schoot, J J M van Dongen.
Abstract
Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detection in ALL (ESG-MRD-ALL), consisting of 30 MRD-PCR laboratories worldwide, has developed guidelines for the interpretation of real-time quantitative PCR-based MRD data. The application of these guidelines ensures identical interpretation of MRD data between different laboratories of the same MRD-based clinical protocol. Furthermore, the ESG-MRD-ALL guidelines will facilitate the comparison of MRD data obtained in different treatment protocols, including those with new drugs.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17287850 DOI： 10.1038/sj.leu.2404586
Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528